Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy
Open Access
- 12 October 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 72 (6), 1283-1290
- https://doi.org/10.1007/s00280-013-2306-7
Abstract
Oxaliplatin-induced peripheral neurotoxicity (OPN) is frequent and potentially severe, but successful treatment of this condition is still an unmet clinical need. We aimed to determine whether treatment with goshajinkigan (TJ-107), a traditional Japanese medicine, is better than placebo in preventing OPN in patients with advanced or recurrent colorectal cancer patients treated with standard FOLFOX regimens. In this phase 2, randomized, double-blind, placebo-controlled study, patients undergoing oxaliplatin-based chemotherapy were randomized to receive either oral TJ-107 (7.5 g) or matching placebo daily. The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week. The primary endpoint was the incidence of grade 2 or greater OPN until the 8th cycle of chemotherapy. Analyses were done by intention to treat. Eighty-nine patients were randomly assigned to receive either TJ-107 (n = 44) or placebo (n = 45) between May 2009 and March 2010. The incidence of grade 2 or greater OPN until the 8th cycle was 39 and 51 % in the TJ-107 and placebo groups, respectively (relative risk (RR), 0.76; 95 % CI, 0.47–1.21). The incidence of grade 3 OPN was 7 % (TJ-107) vs. 13 % (placebo) (0.51, 0.14–1.92). No concerns regarding toxicity emerged with TJ-107 treatment. TJ-107 appears to have an acceptable safety margin and a promising effect in delaying the onset of grade 2 or greater OPN without impairing FOLFOX efficacy.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trialAnnals Of Oncology, 2012
- Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomicsThe Lancet Oncology, 2011
- Effects of protostane-type triterpenoids on the 5-HT3A receptor-mediated ion current in Xenopus oocytesBrain Research, 2010
- Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available toolsEuropean Journal Of Cancer, 2010
- Exodus of Kampo, traditional Japanese medicine, from the complementary and alternative medicines: Is it time yet?Surgery, 2009
- Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy: A Placebo-controlled Double-blind Randomized Phase II Study (the GONE Study)Japanese Journal of Clinical Oncology, 2009
- Oxaliplatin Acts on IB4-Positive Nociceptors to Induce an Oxidative Stress-Dependent Acute Painful Peripheral NeuropathyThe Journal of Pain, 2008
- Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetesDiabetes Research and Clinical Practice, 2005
- Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic ratsDiabetes Research and Clinical Practice, 2003
- Safety of oxaliplatin in the treatment of colorectal cancer.2000